SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

APGE

Apogee Therapeutics
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor the upcoming APEX Phase 2 Part A 52-week data readout this month and the head-to-head APG279 vs. Dupixent data in 2H 2026, which could serve as key catalysts if results show competitive dosing or efficacy advantages.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$70.92
T+0 close · Mar 2, 2026 · via day close
Latest settled
+16.77%
T+60 · $82.81
Vs SPY
+7.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $70.92entry
  2. T+1 · 9mo ago −3.41%α −2.49% · $68.50
  3. T+5 · 8mo ago +5.68%α +6.88% · $74.94
  4. T+20 · 8mo ago +11.01%α +18.94% · $78.72
  5. T+60 · 6mo ago +16.77%α +7.45% · $82.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics reported full-year 2025 financial results with increased R&D and G&A spending driving a wider net loss, while maintaining a strong cash position of $902.9 million that funds operations into 2H 2028. The company highlighted upcoming clinical milestones for its lead asset zumilokibart in atopic dermatitis, asthma, and EoE, including a head-to-head trial against Dupixent with interim data expected in 2H 2026.

Key Facts

  • Cash, cash equivalents, and marketable securities totaled $902.9 million as of December 31, 2025, up from $731.1 million in 2024.
  • R&D expenses increased to $214.7 million in 2025 from $167.9 million in 2024.
  • G&A expenses rose to $70.9 million in 2025 from $49.0 million in 2024.
  • Net loss widened to $255.8 million in 2025 from $182.1 million in 2024.
  • APEX Phase 2 Part A 52-week data for zumilokibart in atopic dermatitis expected in March 2026.
  • Head-to-head Phase 1b trial of APG279 vs. Dupixent in AD to deliver interim data in 2H 2026.

Financial Impact

Increased operating expenses led to a 40% rise in net loss year-over-year, but cash runway extends to 2H 2028.

net lossR&D expenseG&A expensecash runway

Risk Factors

  • Clinical trial results may not meet expectations, particularly in head-to-head comparison with established therapy Dupixent.
  • Increasing operating expenses without near-term revenue could pressure valuation if development timelines extend.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247224

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (11h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026